Successful Phase III study for FV 100 in treatment of post-herpetic neuralgia- ContraVirPharma

ContraVir Pharmaceuticals reported a positive outcome from an important drug-drug interaction study regarding the Company's novel antiviral drug candidate FV-100, which is currently in Phase III clinical development to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

The drug-drug interaction study examined oral co-administration of FV-100 with ritonavir, a known inhibitor of the key drug metabolism enzyme CYP3A and the P-glycoprotein (P-gp) drug transporter, both of which are involved in a large number of adverse drug-drug interactions. FV-100 was safe and well tolerated in this study. Importantly, the results showed that inhibition of CYP3A or P-gp by ritonavir or any other drugs that inhibit CYP3A or P-gp, is unlikely to elicit a clinically significant drug-drug interaction that could compromise the safety or efficacy of FV-100.